Compares 2-dose and 3-dose hepatitis B vaccine schedules in people with cirrhosis
Tests 2-dose versus 3-dose Heplisav B vaccine in adults with cirrhosis.
Plain-language title generated from the registry record
Registry title: Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis
Key facts
- Where
- Baltimore, United StatesSee the site
- Phase
- Phase 4
Where in United States
- Mercy Medical CenterBaltimore, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Mercy Medical Center
- Trial code
- NCT04588077
- Record updated
- 19 November 2024
- Original description
Investigators want to compare the seroconversion rates between two-dose and three-dose regimens of the hepatitis B vaccine (Heplisav B) among patients with cirrhosis, a randomized prospective study.Read full original descriptionShow less
Comparison the Seroconversion Rate Between Two-dose and Three-dose Regimens of Heplisav B Among Patients With Cirrhosis, a Randomized-control Prospective Study.
Investigators want to compare the seroconversion rates between two-dose and three-dose regimens of the hepatitis B vaccine (Heplisav B) among patients with cirrhosis, a randomized prospective study.
Inclusion: All the cirrhosis patients more than 18 years old presented to the hepatology clinic in Mercy Medical Center between 09/2020 and 07/2021 who do not have immunity against Hepatitis B (defined as anti-HBs titer < 10 mIU/ml) will be recruited.
Exclusion: Anyone who has had a serious allergic reaction to a prior dose of the hepatitis B vaccine, a component of the hepatitis B vaccine, or yeast should not receive the hepatitis B vaccine; Those who had previous exposure to hepatitis B; Post liver transplant patients; Less than 18 years old.